Tirzepatide 10mg - 4 Pack

The Tirzepatide 10mg 4-Pack offers researchers substantial value for in-depth investigations into dual incretin receptor activation. This bulk package contains four vials of Tirzepatide, the innovative compound that has rapidly become essential for laboratories studying the synergistic effects of simultaneous GIP and GLP-1 pathway modulation. Designed for research programs requiring extended study durations or multiple experimental arms, this 4-pack supports comprehensive protocols including chronic administration studies, dose-escalation experiments, and head-to-head comparisons with single-receptor agonists. Package Contents 4 × 10mg vials (40mg total) ≥98% purity verified by HPLC Lot-matched Certificate of Analysis Significant per-unit savings For in vitro and in vivo research use only.

FDA-approved for: - Type 2 diabetes (Mounjaro) - Obesity (Zepbound) - NASH research - Cardiovascular outcomes - Sleep apnea studies - PCOS management - Metabolic syndrome - Renal protection studies

Dual GIP/GLP-1 receptor agonist: 1. GLP-1 receptor activation 2. GIP receptor activation (unique) 3. Enhanced insulin secretion 4. Glucagon suppression 5. Delayed gastric emptying 6. Central appetite regulation 7. Improved insulin sensitivity

Superior weight loss (up to 22.5%) Excellent glycemic control Improved insulin sensitivity Cardiovascular benefits Liver fat reduction Better lipid profiles Blood pressure reduction Potential β-cell preservation

FDA-approved dosing: - Starting: 2.5mg weekly for 4 weeks - Titration: Increase by 2.5mg every 4 weeks - Maintenance: 5mg, 10mg, or 15mg weekly - Maximum: 15mg weekly - Same day each week

Common side effects: - Gastrointestinal (nausea, diarrhea) - Decreased appetite - Vomiting - Constipation - Injection site reactions - Fatigue - Rare: pancreatitis, gallbladder - Hypoglycemia (with insulin)